OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity

Rhea-AI Summary

OKYO Pharma Limited announced the issuance of 250,000 new ordinary shares at a price of 4.5p per share due to the exercise of options. This will raise the company's total share capital to 672,816,302 ordinary shares. Applications for admission of these shares have been submitted to the FCA and the London Stock Exchange, with trading expected to commence at 8:00 a.m. on March 3, 2021. This move is part of OKYO's ongoing efforts in developing treatments for inflammatory dry eye diseases and ocular pain.

Positive

• Issuance of 250,000 ordinary shares at 4.5p each may provide additional capital.
• Total share capital increases to 672,816,302 shares, enhancing market presence.

Negative

• None.

LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value ("Ordinary Shares"), credited as fully paid, at a price of 4.5p per share on the exercise of 250,000 options.

Applications will be made to the FCA and to the London Stock Exchange for Admission in respect of all the 250,000 Ordinary Shares. It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 3 March 2021.

Following Admission of the new Ordinary Shares, the enlarged Share Capital will be 672,816,302 ordinary shares of no par value.

The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF UK MARKET ABUSE REGULATION.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.

Enquiries:

OKYO Pharma Limited	Willy Simon	+44 (0)20 7495 2379
Optiva Securities Limited	Robert Emmet	+44 (0)20 3981 4173

For further information, please visit the Company's website at www.okyopharma.com.

FAQ

What is the significance of OKYO Pharma's 250,000 new shares issued on March 3, 2021?

The issuance of 250,000 new shares at 4.5p each is significant as it could provide additional capital for OKYO Pharma's ongoing projects.

What is the current total share capital of OKYO Pharma after the new share issuance?

After the issuance, OKYO Pharma's total share capital will be 672,816,302 ordinary shares.

When will the new shares for OKYO Pharma start trading on the London Stock Exchange?

The new shares are expected to start trading on the London Stock Exchange at 8:00 a.m. on March 3, 2021.

What is the purpose of issuing new shares for OKYO Pharma?

The purpose of issuing new shares is typically to raise capital, which can be used to fund ongoing research and development.